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ABSTRACT

ARTICLE HISTORY

No indigenous cases of poliomyelitis have occurred in the US since 1979; however the risk of importation
persists until global eradication is achieved. The seropositivity rate for different age cohorts with
exposures to different poliovirus vaccine types and wild virus in the US are not presently known.
A convenience sample was conducted in the Kansas City metropolitan area during 2012–2103 with
approximately 100 participants enrolled for each of 5 age cohorts categorized based on vaccine policy
changes over time in the US. Immunization records for poliovirus vaccination were required for
participants <18 y of age. We evaluated the prevalence of serum antibodies to all 3 poliovirus serotypes.
Seroprevalence was evaluated by demographics as well as between polio serotypes.
The overall seroprevalence to poliovirus was 90.7%, 94.4%, and 83.3%, for types 1, 2, and 3, respectively.
Seroprevalence was high (88.6%–96.2%) for all 3 types of poliovirus for the 6–10 y old age group that was
likely to have received a complete schedule of IPV-only vaccination. Children 2–3 y of age, who have not
yet completed their full IPV series, had lower seroprevalence compared with all older age groups for types
1 and 2 (p-value <0. 05).
Seroprevalence was high for all 3 types of poliovirus in the population surveyed. Seroprevalence for
subjects aged 2–3 y was lower than all other age groups for serotypes 1 and 2 highlighting the
importance of completing the recommended poliovirus vaccine series with a booster dose at age 4–6 y.
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Background
Pakistan and Afghanistan remain the only 2 countries where
wild poliovirus (WPV) transmission has never been interrupted.1-3 While the last cases of indigenously acquired WPV
in the United States (US) occurred in 1979, the last WPV case
in a US resident traveling abroad occurred in 1986, and the last
WPV imported case occurred in 1993. Due to continued WPV
transmission in a few remaining areas of the world, the Centers
for Disease Control and Prevention (CDC) has provided
interim vaccination guidance for travel to and from countries
affected by wild poliovirus.4
Additionally, circulating vaccine-derived poliovirus
(cVDPV) must also be eliminated before polio eradication is
achieved.5 cVDPVs can occur from live vaccine virus in areas
of low vaccine coverage. In 2015, cVDPVs represented 30% of
the reported global polio cases.6 From 1997 to 1999, the US
implemented a sequential inactivated poliovirus vaccine (IPV)
– oral poliovirus vaccine (OPV) schedule. Since 2000, the US
has exclusively used IPV to prevent vaccine-associated paralytic
poliovirus cases (VAPP), which averaged 8–10 cases per year in
the US when OPV was routinely recommended.7 Since that
time, the recommended routine schedule is IPV at age 2, 4, and
6–18 months with a booster dose at age 4–6 y. No systematic
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serosurveys for poliovirus antibodies have been conducted in
the US since the return to an all-IPV recommendation after the
initial use of IPV in the 1950s and early 1960s.8,9 In the past,
population based polio serosurveys have not been used to monitor population immunity to polio in the US. This study
describes the ﬁndings of a serosurvey conducted in the Kansas
City metropolitan area during 2012–13.

Results
Study participants
504 persons aged 2–81 y were recruited through Children’s Mercy
Hospital and Turner Medical Center systems in the Kansas City
Metropolitan area in 2012–2013. All participants were interviewed
with a survey instrument and serum samples were obtained. Age
and demographic characteristics are provided in Table 1.
Overall seroprevalence of poliovirus antibody for types 1,
2, and 3
During 2012–2013, among a regional population that was reasonably representative of the racial/ethnic makeup of the census of the Kansas City Metropolitan area and aged 2–81 y,

CONTACT Aaron T. Curns
agc8@cdc.gov
Centers for Disease Control and Prevention, 1600 Clifton Road Mailstop A34, Atlanta, GA 30329, USA.
Color versions of one or more of the ﬁgures in this article can be found online at www.tandfonline.com/khvi.
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Table 1. Characteristics of Serosurvey Participants, Kansas City Metropolitan Area,
2012–2013.
Age (years)
2–3
6–10
11–15
16–50
>50
Race
Black
White
Asian
American Indian/Alaska Native
Native Hawaiian/Paciﬁc Islander
Mixed
Other
Missing
Ethnicity
Hispanic
Non-Hispanic
Missing
US. Born
Yes
No
Missing
Mother US. Born
Yes
No
Missing
Father US. Born
Yes
No
Missing
Traveled abroad in past 10 years
Yes
No
Missing
Household Member Traveled abroad in past 10 years
Yes
No
Missing

Number of participants
100
105
97
102
100
84
366
4
2
1
24
10
13
42
453
9
455
24
25
442
37
25
436
40
28
102
400
2
133
362
9

overall poliovirus seroprevalence for types 1, 2, and 3 was
90.7% (95% CI: 88.1%-93.2%), 94.4% (95% CI: 92.4%-96.5%)
and 83.3% (95% CI: 80.1%-86.6%), respectively. Seroprevalence
was higher for type 2 compared with type 1 and type 3 (p <
0.05 and p < 0.001, respectively) and seroprevalence for type 1
was also higher than type 3 (p D 0.001). For males, seroprevalence to type 1 and type 2 was higher than type 3 (p < 0.05 and
p < 0.001, respectively); for females, seroprevalence to type 2
was higher than type 3 (p D 0.001). For those US. Born, seroprevalence for type 2 was higher compared with type 1 and
type 3 (p < 0.05 and p < 0.001, respectively) and seroprevalence for type 1 was also higher than type 3 (p D 0.001). Similar
results were found for subjects with neither parent born abroad.
Seroprevalence of poliovirus type 1 antibody
Poliovirus seroprevalence was lower among those aged 2–3 y
compared with all other age groups (p < 0.05 for each comparison, Table 2 and Figure 1). No other differences by age group
were found. When stratiﬁed by gender, those aged 2–3 y had a
lower seroprevalence than all other age groups for males (p <
0.05 for each comparison). No other age group differences were
observed for males. No differences by age groups were observed
for females. For those aged 2–3 years, males had a lower seroprevalence than females (p < 0.05).

777

No overall differences were observed when comparing Black
and White race. When stratiﬁed by age group, Blacks had
higher seroprevalence than Whites for the age groups 6–10,
11–15, and >50 y (p < 0.05 for each comparison). The sample
size was insufﬁcient to evaluate differences between other race
categories. No overall differences were observed comparing
Hispanic to Non-Hispanic ethnicity. But when stratiﬁed by age
group, Hispanics had a higher seroprevalence than Non-Hispanics for the 11–15 y age group (p < 0.05).
No overall differences were observed by US birth status,
mother born abroad status, or father born abroad status. But
when stratiﬁed by age group, Non-US born had a higher seroprevalence than US born for the >50 y age group (p < 0.05).
No differences were observed for the 16–50 y age group; the
sample size was insufﬁcient to evaluate differences by the other
age groups for US born status. Subjects with either parent born
abroad had a higher seroprevalence for the 6–10 y age group
and lower seroprevalence for the 16–50 y age group (p <
0.05 for each comparison). No other differences by age group
and either parent born abroad status were observed.
No overall differences were observed for subject travel
abroad or household member travel abroad. But when stratiﬁed
by age group, for the 6–10 y age group, both the subject group
that traveled abroad and the group with household members
who traveled abroad had a higher seroprevalence than the
group that did not travel abroad (p < 0.05 for each comparison). No other differences were observed by age groups for
travel status.
Seroprevalence of poliovirus type 2 antibody
Poliovirus seroprevalence was lower among those aged 2–3 y
compared with all other age groups (p < 0.001 for 11–15 years,
p < 0.05 compared with the other age groups, Table 2). No
other differences by age group were found. When stratiﬁed by
gender, those aged 2–3 y had a lower seroprevalence than all
other age groups for males (p < 0.001 for 11–15 years, p <
0.05 compared with the other age groups). No other differences
between other age groups were observed for males. No differences by age groups were observed for females. No differences
were observed between males and females in each age group.
No overall differences were observed comparing Black and
White race. But when stratiﬁed by age, Blacks had higher seroprevalence than Whites for the age groups 2–3 and 6–10 y (p <
0.05 for each comparison). The sample size was insufﬁcient to
evaluate differences between other race categories. No overall
differences were observed comparing Hispanic to Non-Hispanic ethnicity. But when stratiﬁed by age, Hispanics had a
higher seroprevalence than Non-Hispanics for the 6–10 y age
group (p < 0.05).
No overall differences were observed by US born status,
mother born abroad status, or father born abroad status. But
when stratiﬁed by age, no differences were observed for the 16–
50 and >50 y age group; the sample size was insufﬁcient to
evaluate differences by the other age groups for US born status.
The group either parent born abroad had a higher seroprevalence for the 6–10 age group (p < 0.05). No other differences
by age group and either parent born abroad status was
observed.

778

G. S. WALLACE ET AL.

Table 2. Percent positive by poliovirus serotype among serosurvey participants, Kansas City Metropolitan Area, 2012–2013.
Percent positive (95% Conﬁdence Interval)

Total
Gender
Female
Male
Age Group (yrs)
2–3
6–10
11–15
16–50
>50
Gender and Age
Female
2–3
6–10
11–15
16–50
>50
Male
2–3
6–10
11–15
16–50
>50
Race
Black
White
Asian
American Indian/Alaska Native
Native Hawaiian/Other Paciﬁc Islander
Other
Hispanic
Yes
No
Age & Race
2–3
Black
White
6–10
Black
White
11–15
Black
White
16–50
Black
White
>50
Black
White
Age & Hispanic
2–3
Yes
No
6–10
Yes
No
11–15
Yes
No
16–50
Yes
No
>50
Yes
No
US. Born
Yes
No

Poliovirus Serotype 1

Poliovirus Serotype 2

Poliovirus Serotype 3

90.7 (88.1 – 93.2)

94.4 (92.4 – 96.5)

83.3 (80.1 – 86.6)

93.0 (88.9 – 96.1)
88.3 (84.2 – 92.3)

95.8 (93.2 – 98.2)
93.1 (89.9 – 96.3)

87.9 (83.9 – 91.9)
78.5 (73.4 – 83.7)

80.0 (72.1 – 87.9)
94.3 (89.8 – 98.7)
93.8 (89.0 – 98.6)
93.1 (88.2 – 98.1)
92.0 (86.7 – 97.3)

86.0 (79.2 – 92.8)
96.2 (92.5 – 99.9)
99.0 (97.0 – 100.0)
96.1 (92.3 99.9)
95.0 (90.7 – 99.3)

79.0 (71.0 – 87.0)
88.6 (82.5 – 94.7)
89.7 (83.6 – 95.8)
77.5 (69.3 – 85.6)
82.0 (74.4 – 89.6)

88.0 (79.0 – 97.0)
94.4 (88.3 – 100.0)
95.8 (90.2 – 100.0)
94.5 (88.5 – 100.0)
92.0 (84.5 – 99.5)

92.0 (84.5 – 99.5)
96.3 (91.2 – 100.0)
97.9 (93.9 – 100.0)
98.2 (94.6 – 100.0)
94.0 (87.4 – 100.0)

88.0 (79.0 – 97.0)
90.7 (83.0 – 98.5)
93.8 (86.9 – 100.0)
81.8 (71.6 – 92.0)
86.0 (76.3 – 95.7)

72.0 (59.5 – 84.5)
94.1 (87.6 – 100.0)
91.8 (84.1 – 95.5)
91.5 (83.5 – 99.5)
92.0 (84.5 – 99.5)

80.0 (68.9 – 91.1)
96.1 (90.7 – 100.0)
100.0 (100.0 – 100.0)
93.6 (86.6 – 100.0)
96.0 (90.5 – 100.0)

70.0 (57.3 – 82.7)
86.3 (76.8 – 95.8)
85.7 (75.9 – 95.9)
72.3 (59.5 – 85.2)
78.0 (66.5 – 89.5)

94.0 (89.0 – 99.1)
90.2 (87.1 – 93.2)

96.4 (92.4 – 100.0)
94.0 (91.5 – 96.4)

95.2 (90.7 – 99.8)
80.6 (76.5 – 84.7)

























88.1 (78.3 – 97.9)
90.7 (88.0 – 93.4)

92.9 (85.0 – 100.0)
94.5 (92.4 – 96.6)

83.3 (72.0 – 94.6)
83.7 (80.2 – 87.1)

86.4 (72.0 – 100.0)
78.1 (68.0 – 88.3)

95.5 (86.7 – 100.0)
81.3 (71.7 – 90.8)

100.0 (100.0 – 100.0)
68.8 (57.4 – 80.1)

100.0 (100.0 – 100.0)
92.4 (86.5 – 98.3)

100.0 (100.0 – 100.0)
94.9 (90.1 – 99.8)

100.0 (100.0 – 100.0)
86.1 (78.4 – 93.7)

100.0 (100.0 – 100.0)
91.3 (84.6 – 98.0)

100.0 (100.0 – 100.0)
98.6 (95.7 – 100.0)

100.0 (100.0 – 100.0)
88.4 (80.8 – 96.0)

87.5 (71.2 – 100.0)
97.3 (93.7 – 100.0)

93.8 (81.8 – 100.0)
97.3 (93.7 – 100.0)

81.3 (62.1 – 100.0)
78.7 (69.4 – 88.0)

100.0 (100.0 – 100.0)
89.9 (83.2 – 96.5)

92.9 (79.3 – 100.0)
96.2 (92.0 – 100.0)

92.9 (79.3 – 100.0)
79.7 (70.9 – 88.6)

88.9 (68.3 – 100.0)
79.1 (70.7 – 87.5)

88.9 (68.3 – 100.0)
85.7 (78.5 – 92.9)

77.8 (50.5 – 100.0)
79.1 (70.7 – 87.5)

88.9 (68.3 – 100.0)
94.8 (90.3 – 99.3)

100.0 (100.0 – 100.0)
95.8 (91.8 – 99.8)

100.0 (100.0 – 100.0)
87.5 (80.9 – 94.1)

100.0 (100.0 – 100.0)
93.3 (88.0 – 98.5)

100.0 (100.0 – 100.0)
98.9 (96.7 – 100.0)

100.0 (100.0 – 100.0)
88.8 (82.2 – 95.3)

77.8 (50.5 – 100.0)
94.4 (89.6 – 99.2)

88.9 (68.3 – 100.0)
96.6 (92.9 – 100.0)

77.8 (50.5 – 100.0)
77.5 (68.8 – 86.2)

85.7 (59.7 – 100.0)
92.0 (86.4 – 97.7)

85.7 (59.7 – 100.0)
95.5 (91.1 – 99.8)

57.1 (20.4 – 93.9)
85.2 (77.8 – 92.7)

91.0 (88.3 – 93.6)
83.3 (68.4 – 98.3)

94.7 (92.7 – 96.8)
91.7 (80.6 – 100.0)

83.7 (80.3 – 87.1)
79.2 (62.9 – 95.5)
(Continued on next page)
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Table 2. (Continued).
Percent positive (95% Conﬁdence Interval)

Age & US. Born
2–3
Yes
No
6–10
Yes
No
11–15
Yes
No
16–50
Yes
No
>50
Yes
No
Mother US. Born
Yes
No
Father US. Born
Yes
No
Either Parent non-US. Born
Yes
No
Age and Either Parent non-US. Born
2–3
Yes
No
6–10
Yes
No
11–15
Yes
No
16–50
Yes
No
>50
Yes
No
Traveled Abroad in past 10 years
Yes
No
Age and Traveled Abroad in past 10 years
2–3
Yes
No
6–10
Yes
No
11–15
Yes
No
16–50
Yes
No
>50
Yes
No
Household Member Traveled Abroad in past 10 years
Yes
No
Age and Household Member Traveled Abroad in past 10 years
2–3
Yes
No
6–10
Yes
No

Poliovirus Serotype 1

Poliovirus Serotype 2

Poliovirus Serotype 3

79.2 (71.0 – 87.3)

86.5 (79.6 – 93.3)

79.2 (71.0 – 87.3)

94.7 (90.2 – 99.2)

95.8 (91.7 – 99.8)

88.4 (82.0 – 94.9)

94.4 (89.7 – 99.2)

98.9 (96.7 – 100.0)

90.0 (83.8 – 96.2)

96.5 (92.5 – 100.0)
75.0 (50.4 – 99.6)

97.6 (94.4 – 100.0)
91.7 (76.0 – 100.0)

77.8 (70.1 – 87.5)
75.0 (68.8 – 86.2)

91.0 (85.0 – 97.0)
100.0 (100.0 – 100.0)

95.5 (91.2 – 99.8)
87.5 (64.5 – 100.0)

82.0 (74.0 – 90.0)
87.5 (64.5 – 100.0)

91.0 (88.3 – 93.6)
86.5 (75.4 – 97.5)

94.6 (92.5 – 96.7)
94.6 (87.3 – 100.0)

83.0 (79.5 – 86.5)
89.2 (79.1 – 99.2)

91.5 (88.9 – 94.1)
80.0 (67.6 – 92.4)

95.0 (92.9 – 97.0)
90.0 (80.7 – 99.3)

83.7 (80.2 – 87.2)
80.0 (67.6 – 92.4)

83.0 (72.2 – 93.8)
91.4 (88.7 – 94.0)

91.5 (83.5 – 99.5)
94.9 (92.8 – 97.0)

83.0 (72.2 – 93.8)
83.4 (79.9 – 87.0)

80.0 (55.1 – 100.0)
79.1 (70.4 – 87.7)

80.0 (55.1 – 100.0)
87.2 (80.1 – 94.3)

80.0 (55.1 – 100.0)
79.1 (70.4 – 87.7)

100.0 (100.0 – 100.0)
94.6 (89.9 – 99.2)

100.0 (100.0 – 100.0)
95.7 (91.5 – 99.8)

100.0 (100.0 – 100.0)
87.0 (80.0 – 93.9)

88.9 (68.3 – 100.0)
93.8 (88.6 – 99.1)

100.0 (100.0 – 100.0)
98.8 (96.4 – 100.0)

100.0 (100.0 – 100.0)
88.9 (82.0 – 95.5)

76.5 (56.2 – 96.7)
97.5 (94.1 – 100.0)

94.1 (82.9 – 100.0)
97.5 (94.1 – 100.0)

76.5 (56.2 – 96.7)
78.8 (69.8 – 87.7)

83.3 (53.4 – 100.0)
92.2 (86.7 – 97.8)

83.3 (53.4 – 100.0)
95.7 (91.3 – 99.8)

66.7 (28.8 – 100.0)
83.3 (75.6 – 91.1)

94.1 (89.5 – 98.7)
89.8 (86.8 – 92.7)

97.1 (93.8 – 100.0)
93.8 (91.4 – 96.1)

80.4 (72.7 – 88.1)
84.0 (80.4 – 87.6)

























79.2 (71.0 – 87.3)

86.5 (79.6 – 93.3)

78.1 (69.8 – 86.4)

100.0 (100.0 – 100.0)
93.9 (89.1 – 98.6)

100.0 (100.0 – 100.0)
95.9 (92.0 – 99.8)

71.4 (37.8 – 100.0)
89.8 (83.8 – 95.8)

80.0 (59.7 – 100.0)
96.3 (92.3 – 100.0)

100.0 (100.0 – 100.0)
98.8 (96.4 – 100.0)

80.0 (59.7 – 100.0)
91.5 (85.4 – 97.5)

97.7 (93.3 – 100.0)
89.5 (81.5 – 97.5)

97.7 (93.3 – 100.0)
94.7 (88.9 – 100.0)

75.0 (62.2 – 87.8)
78.9 (68.3 – 89.6)

93.8 (85.3 – 100.0)
91.0 (84.2 – 97.9)

96.9 (90.8 – 100.0)
94.0 (88.3 – 99.7)

87.5 (76.0 – 99.0)
79.1 (69.3 – 88.9)

91.0 (86.1 – 95.9)
90.3 (87.3 – 93.4)

91.7 (87.0 – 96.4)
95.9 (93.8 – 97.9)

80.5 (73.7 – 87.2)
84.5 (80.8 – 88.3)

80.0 (64.3 – 95.7)
79.5 (70.2 – 88.8)

68.0 (49.7 – 86.3)
93.2 (87.3 – 99.0)

72.0 (54.3 – 89.7)
82.2 (73.4 – 91.0)

100.0 (100.0 – 100.0)
92.6 (86.9 – 98.3)

100.0 (100.0 – 100.0)
96.3 (92.2 – 100.0)

97.0 (73.1 – 100.0)
88.9 (82.0 – 95.8)
(Continued on next page)
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Table 2. (Continued).
Percent positive (95% Conﬁdence Interval)

11–15
Yes
No
16–50
Yes
No
>50
Yes
No

Poliovirus Serotype 1

Poliovirus Serotype 2

Poliovirus Serotype 3

89.7 (78.5 – 100.0)
95.3 (90.1 – 100.0)

100.0 (100.0 – 100.0)
98.4 (95.4 – 100.0)

86.2 (73.6 – 98.8)
92.2 (85.6 – 98.8)

93.8 (85.3 – 100.0)
92.8 (86.6 – 98.9)

93.8 (85.3 – 100.0)
97.1 (93.1 – 100.0)

75.0 (59.9 – 90.1)
78.3 (68.5 – 88.0)

91.7 (80.6 – 100.0)
92.0 (85.8 – 98.2)

95.8 (87.8 – 100.0)
94.7 (89.6 – 99.8)

83.3 (68.4 – 98.3)
81.3 (72.5 – 90.2)



Results based on <5 individuals are not presented.

No overall differences were observed for the group that
traveled abroad or had a household member who traveled
abroad. But when stratiﬁed by age, the 6–10 y age group,
those who travel abroad had a higher seroprevalence than
the 6–10 y age group that did not travel abroad (p <
0.05). For the 2–3 y age group, the group with a household member who traveled abroad had a lower seroprevalence than the same age group in which no family
member traveled abroad (p < 0.05). No other differences
were observed by age groups for travel status (sample size
was insufﬁcient to evaluate subject traveled abroad for the
2–3 y age group).

Seroprevalence of poliovirus type 3 antibody
Poliovirus seroprevalence was lower among those aged
2–3 y compared with those aged 11–15 years; those aged
16–50 y had lower seroprevalence than those aged 6–10
and 11–15 y (p < 0.05 for each comparison, Table 2).
When stratiﬁed by gender, males aged 2–3 y had a lower
seroprevalence than the males aged 6–10 y (p < 0.05). No
other differences between age groups were observed for
males and no differences by age groups were observed for
females. For those aged 2–3 years, males had a lower seroprevalence the females (p < 0.05).
Seroprevalence was higher overall for Black race compared
with White (p < 0.001). The sample size was insufﬁcient to
evaluate differences between other race categories. When analyzing age groups by race, Blacks had higher seroprevalence
than Whites for the age groups 2–3, 6–10, and 11–15 y (p <
0.001, p < 0.001, p < 0.05, respectively). No differences were
observed for overall seroprevalence comparing Hispanic to
Non-Hispanic ethnicity. But when analyzing age groups among
Hispanics vs. Non-Hispanics, Hispanics had a higher seroprevalence than Non-Hispanics for the 6–10 and 11–15 y age group
(p 0.001).
No differences were observed for overall seroprevalence
by US born status, mother born abroad status, or father
born abroad status. Analysis by age group showed no differences for the 16–50 and >50 y age group; the sample size
was insufﬁcient to evaluate differences by the other age
groups for US born status. Subjects with either parent born
abroad had a higher seroprevalence for the 6–10 and 11–
15 y age group (p < 0.001, <0.05, respectively). No other

differences by age group and either parent born abroad status was observed.
No differences were observed for travel abroad or having a
household member travel abroad. No differences were observed
when comparing age groups for travel status of subjects or
household members.
Comparison of seroprevalence of poliovirus antibody for
types 1, 2, and 3
Seroprevalence for serotype 2 was higher than serotype 3 for
age groups 6–10, 11–15, 16–50, and >50 y (p < 0.05, p < 0.05,
p < 0.001, and p < 0.05, respectively, Figure 1). Seroprevalence
for serotype 1 was higher than serotype 3 for age groups 16–50
and >50 y (p < 0.05 for each comparison). No other differences between serotypes by age group were observed.
Seroprevalence for serotype 3 was lower than serotype 1 and
2 for Whites (p < 0.001). There were no signiﬁcant differences
for Blacks. Seroprevalence for non-Hispanics was higher for
serotype 1 compared with serotype 3, and for serotype 2 compared with serotype 1 and 3 (p D 0.001, p < 0.05, p < 0.001,
respectively).
Seroprevalence for non-U.S born was higher for serotype 1
compared with serotype 3, and for serotype 2 compared with
serotype 1 and 3 (p D 0.001, p < 0.05, p < 0.001, respectively).
Seroprevalence for the group with mother not born abroad was
higher compared with the group with a mother born abroad
for serotype 1 compared with serotype 3, and for serotype 2
compared with serotype 1 and 3 (p < 0.001, p < 0.05,
p < 0.001, respectively). Seroprevalence for father not born
abroad was higher compared with the group with father born
abroad for serotype 1 compared with serotype 3, and for serotype 2 compared with serotypes 1 and 3 (p < 0.001, p < 0.05,
p < 0.001, respectively).
Seroprevalence by vaccine status
All subjects aged <18 y with documentation of no poliovirus vaccine were negative for all 3 serotypes (N D 5). Seven
of 100 subjects aged 2–3 y were negative to all 3 serotypes
(2 unvaccinated, 1 with one poliovirus vaccine dose, 1 with
2 doses, and 3 with 3 doses). Five of 209 6–17 y old subjects, who were eligible for a complete poliovirus vaccine
schedule, were negative to all 3 serotypes (3 unvaccinated
and 2 with a complete vaccine schedule of 4 or 5 vaccine

HUMAN VACCINES & IMMUNOTHERAPEUTICS

781

Figure 1. Seroprevalence of poliovirus antibodies by age group, Kansas City Metropolitan Area, 2012–2013.

doses). Two of 195 subjects aged  18 y were negative to all
3 serotypes (vaccine records unavailable).

Discussion
Overall seroprevalence for antibodies against poliovirus serotypes 1–3 was high in the study population aged 2–81 y during
2012–2013 consistent with high vaccine coverage in the study
and in the overall United States. Of note, seroprevalence for
subjects aged 2–3 y was lower than all other age groups for
serotypes 1 and 2, highlighting the importance of completing
the recommended poliovirus vaccine series with a booster dose
at age 4–6 y. The seroprevalence levels in this age group were
lower than what was found during the transition for OPV to
IPV among subject that were ﬁrst eligible for an all-IPV schedule.9 This may be due to children no longer being exposed to
live-vaccine virus either through vaccine or environmentally.
Differences by age group for serotype 3 were not consistent
(e.g. 2–3 y were lower than 11–15 years; 16–50 y were lower
than 6–10 and 11–15 y olds) although the lower seroimmunity
of type 3 is well known and consistent with previous ﬁndings
and the known immunogenicity differences among serotypes
in the vaccine. In some subcategories, males had a lower seroprevalence than females; however, this was not a universal ﬁnding and did not ﬁt a consistent pattern. Similarly, Blacks had
higher seroprevalence than Whites, and Hispanics had higher
seroprevalence than non-Hispanics in some subcategories.
Birthplace of subjects and parents and travel history of subjects
and household members showed differences in seroprevalence
in a small number of subcategories. Lower seroprevalence
among some subgroups may indicate certain subpopulations
may be at increased risk for transmission and outbreaks if
poliovirus was introduced; however, the seroprevalence among
all subgroups evaluated was near or above the expected crude
herd immunity threshold in a developed country, which has
been estimated at a range of 80–86%.10 On an individual level,
seronegativity to one or more serotypes may still be protective
if individuals were primed because they were previously vaccinated or exposed to poliovirus. Nevertheless, given that overall
seronegativity rates were 9.3%, 5.6%, and 16.7% for serotypes 1,
2, and 3, respectively, there remains some low level of

susceptibility. As long as poliovirus circulation continues anywhere in the world, importations remain a risk and consequently, there remains a limited risk of possible outbreaks
among unvaccinated subpopulations.
This study has some limitations. The analyses relied on data
from a sampling of participants in the Kansas City metropolitan
area and it is unknown if these results are generalizable to the current status of poliovirus immunity in the US population as a
whole. A larger, national based serosurvey was recently published,
but did not cover the youngest age groups and did not have vaccine records available.11 In addition, vaccination history was
obtained only for those aged <18 years, so we were unable to distinguish between immunity due to infection versus vaccination for
the older ages. Among US born persons, natural infection would
be expected to be very rare since circulation of WPV has been at
an extremely low level (or zero) in the US during the lifetime of all
but the oldest of study subjects. Acquisition of infection by a USborn person while traveling abroad is a possibility, but is also likely
to be relatively rare. Finally, the proportion of individuals that
were surveyed and tested varied by age group, race/ethnicity, and
US birth status, and the study may not identify small subgroups
with increased susceptibility to polio due to the small sample size.
Results from this study indicate high seroprevalence to poliovirus in the subjects surveyed in the Kansas City metropolitan
area aged 2–81 y. These results provide evidence to support prevention of sustained disease transmission if poliovirus is
imported into the US. The lower seroprevalence in younger children also highlight the importance of completing the recommended poliovirus vaccine series, including a booster dose at
4–6 y. This result may inﬂuence global polio vaccine policy with
the switch to an IPV only schedule. WPV remains endemic in
only 3 countries, limiting the risk of importation to the US, but
not eliminating it. Monitoring seroprevalence is an important
component of understanding risks for polio in the US. Continued high vaccine coverage remains paramount in the near future
while the world completes the global elimination of polio.

Materials and methods
A convenience sample of participants was enrolled from
patients and volunteers (employees and employee referrals)
from Children’s Mercy Hospital and Clinics (CMH) and
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Truman Medical Center-Lakewood (TMC) serving the Kansas City metropolitan area. Informed consent was obtained
from all participants or their legal guardians, and the Institutional Review Board of CDC, CMH, and TMC approved
the protocol. The sampling was designed within each cohort
to represent a reasonable distribution similar to the racial/
ethnic diversity of the Kansas City metropolitan area as
determined by the census and be split equally between genders. From the 2005 census, the Kansas City metropolitan
area was 74% white, 16% black, 6% Hispanic, 1% Asian,
and 3% other compared with 66%, 17%, 7%, 1%, and 9%,
respectively in the study group. Additional information was
gathered regarding country of birth (US born vs. not US
born) for subjects and each of their parents as well as travel
abroad in the previous 10 y for the subject and household
members. To be eligible, documentation of vaccine status
was required for subjects <18 y of age. Written documentation of immunization by provider record, parental record,
or registries was acceptable. Parental recall of immunization
was not accepted. Those with medical conditions that may
impact immune status were excluded, speciﬁcally persons
who are on cancer chemotherapy, who have active HIV/
AIDS, have received a stem cell or organ transplant,
received blood products including IVIG within the past
6 months, or have taken high doses of corticosteroids
( 2 mg/kg/day) on a daily basis within the past 3 months.
Seroprevalence for antibodies against poliovirus serotypes
1–3 were compared by demographic characteristics for 504
individuals aged 2 to 81 y who participated in the 2012–2013
study. The following age cohorts were recruited with the goal
of »100 subjects per cohort:
 Age 2–3 y representing children recommended for an allIPV primary series before their 4–6 y old booster;
 Age 6–10 y representing children recommended for an
all-IPV series including the 4–6 y old booster;
 Age 11–15 y which would include individuals during the
transition from an all-OPV recommendation to an allIPV recommendation;
 Age 16–50 y which would include individuals born before
the transition from an all-OPV recommendation to an
all-IPV recommendation;
 Age >50 y which would include individuals born when
vaccine was being introduced (IPV and OPV) and
pre-vaccine era.
Serum samples from participants were tested for poliovirusspeciﬁc antibodies. Samples were tested using a standard microneutralization assay for antibodies to poliovirus types 1, 2, and 3,
according to established protocols at the Polio Global Specialized
Laboratory, CDC.12 Brieﬂy, 80–100 CCID50 (50% cell culture
infectious dose) of each poliovirus serotype and 2-fold serial dilutions of serum were separately combined and pre-incubated at
35 C for 3 hours before addition of HEp-2(C) cells (human cervix carcinoma cell line). After incubation for 5 d at 35 C and
5% CO2, plates were stained with crystal violet and cell viability
measured by optical density in a plate spectrophotometer. Each
specimen was run in triplicate, with parallel specimens from one
study subject tested in the same assay run, and the neutralization
titers estimated by the Spearman-K€arber method and reported
as the reciprocal of the calculated 50% end point.13 Each run

contained multiple replicates of a reference antiserum pool to
monitor performance variation. A serum sample was considered
positive if the 50% end point titer was  1:8 dilution.
The data were analyzed using SUDAAN 11.0 (Research Triangle Institute, Research Triangle Park, NC) and SAS 9.3 (SAS
Institute, Cary NC): t-tests were used to evaluate differences in
seroprevalence by demographic characteristics and serotype. Pvalues <0.05 were considered statistically signiﬁcant and were
not adjusted for multiple comparisons. Results based on <5
individuals were excluded from the analysis and not reported.

Disclaimer
The ﬁndings and conclusions in this report are those of the authors and do
not necessarily represent the ofﬁcial position of the CDC or Children’s
Mercy Hospital and Clinics.
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